BR112021022347A2 - Processos e intermediários para a preparação de um inibidor de btk - Google Patents

Processos e intermediários para a preparação de um inibidor de btk

Info

Publication number
BR112021022347A2
BR112021022347A2 BR112021022347A BR112021022347A BR112021022347A2 BR 112021022347 A2 BR112021022347 A2 BR 112021022347A2 BR 112021022347 A BR112021022347 A BR 112021022347A BR 112021022347 A BR112021022347 A BR 112021022347A BR 112021022347 A2 BR112021022347 A2 BR 112021022347A2
Authority
BR
Brazil
Prior art keywords
preparation
intermediates
processes
btk inhibitor
btk
Prior art date
Application number
BR112021022347A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021022347A8 (pt
Inventor
Andras Horvath
Yi Chen Cheng
Jinxiong Su
James Pye Philip
Shuo Wang
Albert Wagschal Simon
Yuanyuan Yuan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021022347A8 publication Critical patent/BR112021022347A8/pt
Publication of BR112021022347A2 publication Critical patent/BR112021022347A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112021022347A 2019-05-21 2020-05-20 Processos e intermediários para a preparação de um inibidor de btk BR112021022347A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019087823 2019-05-21
PCT/EP2020/064123 WO2020234381A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a btk inhibitor

Publications (2)

Publication Number Publication Date
BR112021022347A8 BR112021022347A8 (pt) 2021-12-28
BR112021022347A2 true BR112021022347A2 (pt) 2022-01-04

Family

ID=70857160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022347A BR112021022347A2 (pt) 2019-05-21 2020-05-20 Processos e intermediários para a preparação de um inibidor de btk

Country Status (11)

Country Link
US (1) US12215110B2 (https=)
EP (1) EP3972977A1 (https=)
JP (1) JP7658916B2 (https=)
KR (1) KR20220011668A (https=)
CN (1) CN113874378A (https=)
AU (1) AU2020278162A1 (https=)
BR (1) BR112021022347A2 (https=)
CA (1) CA3135240A1 (https=)
IL (1) IL288154A (https=)
MX (1) MX2021014246A (https=)
WO (1) WO2020234381A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12450495B2 (en) 2022-06-13 2025-10-21 International Business Machines Corporation Neural capacitance: neural network selection via edge dynamics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2526933T3 (en) * 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
PT2414363E (pt) * 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
CA2901510C (en) * 2013-03-15 2022-11-29 Janssen Pharmaceutica Nv Processes for preparing ibrutinib derivatives and intermediates thereof
SI3057969T1 (sl) 2013-10-17 2018-10-30 Blueprint Medicines Corporation Sestavki, uporabni za zdravljenje motenj, povezanih s KIT
MA41350A (fr) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
JP6681922B2 (ja) 2015-02-12 2020-04-15 上▲海▼度▲徳▼医▲藥▼科技有限公司 イブルチニブの製造方法

Also Published As

Publication number Publication date
EP3972977A1 (en) 2022-03-30
KR20220011668A (ko) 2022-01-28
AU2020278162A1 (en) 2021-11-18
IL288154A (en) 2022-01-01
BR112021022347A8 (pt) 2021-12-28
US20220204516A1 (en) 2022-06-30
JP7658916B2 (ja) 2025-04-08
JP2022533747A (ja) 2022-07-25
CN113874378A (zh) 2021-12-31
MX2021014246A (es) 2022-01-06
CA3135240A1 (en) 2020-11-26
WO2020234381A1 (en) 2020-11-26
US12215110B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
BR112018001400A2 (pt) compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes
BR112022002375A2 (pt) Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl
UY30662A1 (es) Método de cristalizacion discontinuo para cristalizar un anticuerpo anti-htnfalfa, cristales de anticuerpo obtenido por dicho método, composiciones que los conitenen y aplicaciones
DOP2019000087A (es) Compuestos químicos
BR112023024005A2 (pt) Compostos, composição e processo para preparar compostos de fórmula i
BR112017020993A2 (pt) compostos, processo para a síntese de compostos, composição, uso de um composto da fórmula i, método para combater fungos fitopatogênicos, e, semente.
BR112022005472A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica
BR112017007969A2 (pt) método para produção de e-caprolactama
BR112017028322A2 (pt) compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i
MX385690B (es) Método novedoso para producir 4,5-dihidroisoxazol 5,5-disustituido.
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
BR112018006519A2 (pt) compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente
BR112019005886A2 (pt) tratamento com água de material lipídico
BR112022002060A2 (pt) Síntese de escala de processo de um inibidor de calicreína de plasma
BR112023018654A2 (pt) Compostos antibacterianos
BRPI0816868A8 (pt) Processo para a preparação de derivados de 2,2-difluoroetilamina, intermediários, seu uso e seu processo de preparação
MX2016000390A (es) Proceso para fabricar haloacetamidas.
BR112023018655A2 (pt) Compostos antibacterianos
BR112021022347A2 (pt) Processos e intermediários para a preparação de um inibidor de btk
BRPI0816830A8 (pt) Processo para a preparação de derivados de 2,2-diflúor-etilamina por hidrogenação de amida
BR112022002815A2 (pt) Método para preparar 2-(fenilimino)-3-alquil-1,3-tiazolidin- 4-onas
BR112015007821A2 (pt) processo para a preparação de voriconazol e análogos do mesmo
BR112022005449A2 (pt) Compostos antibacterianos
BR112022005068A2 (pt) Compostos antibacterianos de 4-quinolinona

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.